Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the long-term safety and tolerability of NKTR-118 treatment of opioid-induced constipation (OIC) in patients with non-cancer-related pain.


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01336205
Study type Interventional
Source AstraZeneca
Contact
Status Completed
Phase Phase 3
Start date April 2011
Completion date December 2012

See also
  Status Clinical Trial Phase
Completed NCT01333540 - A Study to Assess the Safety, Tolerability and Clinical Activity of TD-1211 in Patients With Opioid-Induced Constipation Phase 2
Completed NCT01309841 - Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation Phase 3
Completed NCT01323790 - Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation Phase 3
Completed NCT01395524 - A 12-week Extension of the Phase III Study (D3820C00004) to Assess the Effect and Safety of NKTR-118 in Patients With Non-cancer-related Pain and Opioid-induced Constipation Phase 3
Recruiting NCT05588323 - Safety and Pharmacokinetics Study of Naldemedine in Paediatric Participants Receiving Opioids Phase 1/Phase 2